Revvity, Inc. · NYSE:RVTY
Revvity — J.P. Morgan Healthcare Conference 2025
21 slides from Revvity's conference presentation, Jan 13, 2025
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference January 13, 2025
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial r
Slide 3: Financial Disclosures
Segment and business unit financial metrics presented and discussed today reflect management’s estimates of the Company’s new operating and reporting structure that became effective in Fiscal Year 2025 (December 30, 2024), and are subject to change Estimated future results and historical growth rates
Slide 4: This is the story you are going to hear
“This is the story you are going to hear… we’re revolutionizing science and transforming human lives with groundbreaking innovation.” 4
Slide 5: We reimagined our portfolio by acquiring leading scientific offerings and expertise
We reimagined our portfolio by acquiring leading scientific offerings and expertise Legacy Today Acquired substantial Divested Where we started new capabilities Analytical Analytical 1/3 Analytical Large Horizon business Molecule across Food Category of One Nexcelom and Applied markets Enhanced scien
Slide 6: Revvity at-a-glance
Revvity at-a-glance An innovative and differentiated Life Sciences and Diagnostics company ~$2.8B in revenue (2024E) ~25% EMEA Segments Geography Products ~50% ~50% ~30% ~45% ~80% ~20% Life Sciences Diagnostics APAC Americas Recurring Non-recurring Revenue* Revenue *Consumables, services and softwar
Slide 7: Uniquely positioned in specialized, high-growth markets
Life Sciences Diagnostics Providing reagents, instruments, Providing assays, instruments, software and technology services, software and clinical lab services, Overview enabling pre-clinical R&D discovery enabling precision medicine and Uniquely and drug development specialty diagnostic testing posi
Slide 8: Life Sciences at-a-glance
Life Sciences at-a-glance ~15% Market overview Software HSD 5-year historical average organic $30B+ ~$1.4B growth TAM Segment Revenue (2024E) ~33% ~85% Adjusted operating MSD margin (2024E) 5-year market CAGR Life Sciences Solutions Highly innovative reagents Transformed Full solutions to enhance Pu
Slide 9: Strong competitive positioning in innovative areas of Life Sciences
Strong competitive positioning in innovative areas of Life Sciences Key areas of focus Gene and cell modulation Reagents Investigating the function of genes, proteins and cells to accelerate >75k research and drive discovery Reagents offered Cell analysis reagents Microscopy reagents Leading instrum
Slide 10: Diagnostics at-a-glance
Diagnostics at-a-glance ~60% Market overview Immunodiagnostics MSD 5-year historical average organic $30B+ ~$1.4B growth TAM Segment Revenue (2024E) ~27% Adjusted operating MSD ~40% margin (2024E) 5-year market CAGR Reproductive Health Market-leading specialty Complete solutions for screening, early
Slide 11: Comprehensive solutions for high-precision clinical testing
Comprehensive solutions for high-precision clinical testing Key areas of focus Autoimmunity Wide range of assays and innovative automation and allergy platforms for fast and accurate diagnostics Autoimmune assays Automated analyzers Emerging Extensive suite of assays to assess acute and ongoing infe
Slide 12: Bridging the gap from discovery to cure
Bridging the gap from discovery to cure as a key player in high-value areas of the drug development lifecycle Discovery and development Diagnosis to cure Pre-clinical Diagnostics Discovery Clinical Commercial Screening development and monitoring Providing specialty Advanced Robust data Precise tools
Slide 13: Uniquely differentiated in three ways
APPROACH Uniquely differentiated PRODUCTS in three ways: POSITIONING 13
Slide 14: Serving our customers as strategic partners
Serving our customers as APPROACH strategic partners Supporting Pre-clinical Manufacturing Specialty Strategic partnerships drug drug drug clinical with Pharma / Biotech discovery evaluation components diagnostics across our portfolio to drive additional upside vs. the underlying market 14
Slide 15: Providing high-value, non-commoditized offerings
Providing high-value, PRODUCTS non-commoditized offerings Examples of unique products: Life Sciences Diagnostics Automated Indirect Novel Antibodies and Automated Newborn Research Platform Immunofluorescence Specialty Reagents Screening Workflow Testing Autoimmune TotalSeqTM Eonis Q System UNIQO 160 T
Slide 16: Driving faster growth and greater profitability
Driving faster growth and greater POSITIONING profitability… Business Unit LRP Growth Positioning Profile • Cutting-edge scientific innovation drives Immunodiagnostics strong competitive positioning ~40% 9-11% • Strong recurring revenue mix with elevated Software incremental margins • Differentiated an
Slide 17: Supported by the implementation of our transformed operating model
…Supported by the implementation of our transformed operating model The Revvity Business Model Accountability Agility Digitalization Talent Articulating consistent Propelling internal innovation Building dynamic enterprise Establishing a strong operating philosophies to and technological advancement
Slide 18: Strong and differentiated financial outlook
Strong and differentiated financial outlook Long-term outlook 6-8% 3% Double Digits Adj. EPS growth Organic revenue growth 75bps operating (200bps above market) margin expansion Life Sciences: 7-9% Diagnostics: 6-8% Future capital deployment is incremental to the LRP outlook above 18
Slide 19: Financial considerations for 2025
Financial considerations for 2025 Market Margin Net Interest Tax Rate Environment Expansion Expense Path to To be dependent normalization on level of organic to continue into growth; significant ~$70M ~20% 2025 opportunity remains Formal 2025 guidance to be provided during earnings call on January 31
Slide 20: Bringing it all together
Bringing it all together A Category of One An innovative Life Well-positioned with A strategic partner A company with a A differentiated Sciences and high recurring revenue to customers bridging transformed portfolio financial profile Diagnostics company along with compelling the gap from pre-clinical
Slide 21: Expanding the boundaries of human potential through science
Expanding the boundaries of human potential through science 21